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ABSTRACT 
This review narrates the importance of the statin-based molecules and their inherent challenges during their administration. The chronological 
appearance of the statin, their source and the journey with time so to evolve as one of the successful cholesterol-lowering agents to prevent the 
morbidity and mortality especially related to coronary heart disease have been illustrated along with their recent utilities in neurodegenerative 
diseases. The statins, because of their respective physicochemical characters pose several challenges in regards to their effective administration to 
the patients. One of the major issues related their poor bioavailability is their aqueous solubility. The different approaches for the enhancement of 
solubility and hence bioavailability have been discussed systematically. This review finally suggests the importance of more related research in 
regards to their successful administration so to have greater realization of therapeutics efficiency. 
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INTRODUCTION 
The solubility enhancement of the Active Pharmaceutical 
Ingredients (APIs) is one of the important tasks in the field of 
pharmaceutical technology that needs to be addressed by the 
researchers as it may limit their efficacy and utility [1]. Poor 
aqueous solubility of APIs results in a low drug absorption hence 
inadequate and variable bioavailability [2]. Hence the phenomenon 
of solubility is an area of particular important. The development of 
suitable and viable method of solubilisation is very important during 
product development [3]. The discovery of new unknown molecules 
with potent pharmacological activities is costly and difficult. More 
and more researchers either from industries or academia are 
focusing on the molecules which are established as a drug, but 
suffering with some drawback such as low aqueous solubility [4].  
Since the introduction of the Biopharmaceutical Classification 
System (BCS) by Amidon in 1995 [5], it has become an important 
research tools in classifying drug molecules based on their 
bioavailability. This system is classified on the basis of their aqueous 
solubility and intestinal permeability. Solubility and permeability 
are two key parameters responsible for effective bioavailability and 
good in vitro and in vivo correlation [6]. In general drug can be 
classified into 4 classes as per table 1. 
 
Table 1: Biopharmaceutical drug classification system [5] 
Class Permeability Solubility 
I-Well absorbed and their absorption rate is higher than excretion High High 
II-The bioavailability is limited by the solvation rate. A correlation between in vivo bioavailability and in vitro 
solvation can be found. 
High Low 
III-The absorption is limited by the permeation rate with fast solvation rate. Low High 
IV-The bioavailability is poor. Usually not well absorbed over the intestinal mucosa and a high variability is expected. Low Low 
 
As illustrated in table 1, class II drugs which have low aqueous 
solubility and high permeability become the main target for the 
improvement of their solubility. By improving the aqueous solubility 
of these molecules will lead to the improvement of their oral 
bioavailability [7]. In this context, statin molecules the well-known 
hypolipidemic drugs are classified as class II drug as per BCS [8].  
The main objective of this article is to review the various techniques 
and procedures that have been in use by researchers to enhance the 
solubility of statin molecules. We searched Google scholar, 
MEDLINE, EMBASE, Web of Science, ISI Proceedings and BIOSIS 
Previews bibliographic databases using search terms such as statin 
history, characteristics, solubility and solubility enhancement 
techniques. The review is based on the scientific articles published 
in between January 2000–December 2015. In the later part of the 
article the potential current techniques choose need to be 
considered in order to improve the solubility shall also be discussed.  
Cholesterol and coronary heart disease relationship 
The link between cholesterol and Coronary Heart Disease (CHD) was 
not established until it was reported by Dawber in 1950 [9]. Prior to 
that, the physicians were skeptical of any link between cholesterol 
and CHD. This is due to the fact that most patients diagnosed with 
CHD are recorded with insignificant difference in plasma cholesterol 
level than those of the general population [10]. Research led by 
Dawber in 1950 established significant correlation between high plasma 
cholesterol and CHD mortality [11]. The outcomes of the study was then 
supported by another study led by Mariottia [12] which reported that 
CHD mortality rate were high with the increased of plasma cholesterol in 
european country and the United States. Contrary to that, southern 
europe and Japan which reported low plasma cholesterol level had 
substantially recorded lower CHD mortality. Later studies by various 
researchers [13-19] established that Low density lipoprotein (LDL) 
cholesterol which comprises 70% of total cholesterol, together with 
triglycerides promotes the formation of atherosclerotic plaques. The 
lipid hypothesis was then born that proposed elevated LDL cholesterol 
and triglyceride together with the lower High Density Lipoprotein (HDL) 
to increase the risk of CHD.  
Cholesterol biosynthesis 
Most mammalian cells can produce cholesterol through cholesterol 
biosynthesis pathway. This complex process involved more than 30 
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enzymes and the details pathway was extensively studied in the 
1950-1960s [20]. The simplified version of the biosynthesis was 
reduced in fig. 1. An early attempt to reduce cholesterol biosynthesis 
was not successfully encouraged when triparanol introduced in mid-
1960 for the clinical trial was withdrawn from the market after it 
developed cataract and tissue accumulation of desmosterol, the 
substrate for the inhibited enzyme [21]. 
The discovery and history of statin  
Hydroxymethylglutarate, the substrate of HMG-CoA reductase is a 
water soluble compound which can breakdown with alternative 
metabolic pathways, as its concentration builds up in the body. This 
condition reduced the buildup of toxic precursors that might be 
accumulated if the competitive inhibitors are being used [20]. Based 
on those factor, a new compound which can act as an inhibitor of 
HMGA-CoA reductase become an attractive target to be explored by 
the scientist in the mid 70’s. The first HMGA-Co A reductase 
inhibitor, mevastatin was discovered by Endo in 1976, as a fungal 
product extracted from Penicillium citrinu [22]. Mevastatin was 
found to be effective in lowering the plasma cholesterol of rabbit 
[23], monkey [24] and dog [25]. Its prototype trial then began in 
1980 and indicated to be highly effective in lowering the total and 
LDL cholesterol in human plasma [26]. But in September 1980 its 
clinical trial was terminated due to the serious animal toxicity issue. 
At the same time, a group of scientist from Merck found a potent 
HMGA-CoA inhibitor named lovastatin from the fungal product 
extracted from the fermentation broth of Aspergillus terries [27]. The 
first clinical trial was done in mid 1980‘s on lovastatin and found to 
be effective in lowering down plasma LDL cholesterol of healthy 
human volunteers with no obvious adverse effect [28]. The phase II 
clinical study was done in 1984 and the results indicated lovastatin 
to be effective in patients with CHD, non-familial 
hypercholesterolemia and heterozygous FH23 [29]. The phase III 
clinical study in 1988 [30] and 1990 [31]reported that lovastatin 
resulted a large reduction in LDL cholesterol, the lesser extent in 
plasma triglyceride and minimal increased in HDL cholesterol with 
minimal adverse effects than that of the controlled agents 
cholestyramine and probucol. Due to promising clinical trial results, 
USFDA approved the usage of the drug in August 1987 [20] and 
lovastatin became available for prescription use at the end of 80’s and 
showed a mean reduction of 40% LDL cholesterol through daily dosing 
of 80 mg [29]. This drug was rapidly accepted by the physicians and 
patients due it's few adverse effects and easy patient compliance. The 
phase IV clinical trial which involved a larger number of patients (more 
than 8000) was carried out in 1991 which further proved its efficacy and 
patient tolerability [32]. The success of lovastatin catalyze the 
discoveries of another group of statin such as simvastatin in 1988, 
pravastatin in 1991, fluvastatin in 1994, atorvastatin in 1997, 
cerivastatin in 1998, pitavastatin in 2002 and rosuvastatin in 2003 [20]. 
Statin molecules 
Chemistry and functional properties 
Statin molecules can be divided into 3 classes based on their origin. 
As mentioned previously, lovastatin is derived naturally from the 
fungal product of Aspergillus terries. Simvastatin is a semi-synthetic 
derivative of lovastatin (it has additional side chain methyl group) 
and pravastatin is derived semi-synthetically from mevastatin by 
biotransformation process [17]. Fluvastatin, atorvastatin, cerivastatin, 
pitavastatin and rosuvastatin are synthetically synthesized. Fluvastatin 
has a very different structure from statin derived from the fungal 
product. It is a mevalonolactone derivative with fluorophenyl-
substituted indole ring. Another synthetic statin has a similar structure 
with flurophenyl group with open ring acid forms. (fig. 2) [33]. Based on 
its molecular structure (fig. 2), simvastatin, atorvastatin, fluvastatin and 
lovastatin are relatively lipophilic in nature, while pravastatin and 
rosuvastatin are more hydrophilic due to the presence of polar hydroxyl 
group and methane sulphonamide group respectively on their molecular 
structure. 
Mechanisms for the action of statins 
Study by Istvan [34] revealed that statin act by binding to the active 
side of the enzyme (HMG-CoA reductase) therefore preventing the 
substrate (HMG-CoA) to binding. Its unique binding affinity towards 
the enzyme which is in the nanomolar range compared to the 
micromolar range for the substrate contributes to its specificity and 
competitive inhibitors characteristics [35]. Different type of statin 
shows different modes of binding with HMG CoA reductase. In the 
case of atorvastatin, an additional hydrogen bond was demonstrated 
in the atorvastatin–enzyme complex which resulted in more binding 
interaction with the substrate. These characteristics differentiate 
their pharmacokinetics properties and pharmacological effects [17]. 
The inhibition of HMG-CoA reductase resulted in the reduction of 
cholesterol synthesized by the hepatocyte. The reduction in 
intracellular cholesterol concentration induced hepatic LDL-
receptor, which results in increased extraction of LDL-C from the 
blood and decreased circulating LDL-C concentrations [36]. 
 
 
Fig. 1: Cholesterol biosynthesis pathway 
  
Pharmacokinetic properties 
Statin molecules exist in two forms ie lactone (prodrug) and open 
ring hydroxyl acid. The hydroxyl acid forms are the active form of 
drug which can lower the plasma cholesterol in vivo. The lactone 
form of statin will be transformed into the active form in the liver 
and non-hepatic tissue [37]. Lovastatin and simvastatin are an 
inactive lactone prodrug. The lactone is absorbed from GIT Tract 
and hydrolyzed rapidly by cytochrome P450 3A4 in the liver to form 
β-hydroxyacid metabolite [30, 38]. Another statin is administered as 
their hydroxyl acid active form. After oral administration, all statin 
are absorbed rapidly reaching maximum plasma concentration Tmax 
within 4 h [39-41] atorvastatin, pitavastatin and rosuvastatin rate 
and extent of absorption was not affected by the time of day of its 
administration. This is contributed by their long half-life 
characteristic which recorded at 14h, 11h to 19h respectively. Other 
statins which have a shorter half-life ranging from 1.2h–3h are best 
administered in the evening, when the rate of endogenous 
cholesterol synthesis is highest [39-41]. The long half-life 
characteristics of atorvastatin, pitavastatin and rosuvastatin also 
contribute to their greater efficacy for lowering LDL-C compared 
with other statins [42]. With the exception of pitavastatin and 
cerivastatin, most of the statin possesses low systemic 
bioavailability ranging from 5%-24% [43, 44]. This is due to the 
several factors such as low solubility in water [45], transmembrane 
efflux via P-glycoprotein [46] and extensive metabolism in the liver 
and guts [47]. 
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Fig. 2: Commercialized statins molecular structures 
 
With the exception of pravastatin, all statins are extensively bound 
to plasma proteins (ranging from 95%-98%) [48]. Due to this factor, 
the concentration of the active drug in the systemic system is 
relatively low and reduces their pharmacological activities. In the 
case of pravastatin, although circulating levels of unbound 
pravastatin in the systemic system is very high, its hydrophilic 
characteristic limits its tissue distribution [48, 36]. 
Statins are primarily metabolized by the cytochrome P450 (CYP450) 
family of enzymes, which consist of more than 30 isoenzymes [49]. 
Simvastatin, atorvastatin and lovastatin is metabolized by the 
CYP3A4 isoenzyme whereas fluvastatin is mainly metabolized by the 
CYP2C9 isoenzyme. Other statins such as pravastatin, pitavastatin 
and rosuvastatin do not significantly metabolized through CYP450 
pathways [50]. Recent studies show that statin molecules which 
metabolized by the CYP450 system particularly CYP3A4 isozyme are 
more prone to lead to muscle toxicity issue [51, 52]. Other drug 
interaction with a statin might increase statin concentration in 
plasma with a consequent increased risk of toxic effects. Most statin 
undergoes extensive metabolism in the liver and mainly excreted in 
the bile [42]. Due to this factor, the incident of statin-induced 
myopathy was high for hepatic dysfunction patient [53]. Pravastatin 
and rosuvastatin, on the other hand, are eliminated as an unchanged 
drug by kidney and liver [54, 55]. 
Efficacy and safety of statins 
As the most commonly prescribe lipid modifying drugs, statins are 
highly effective at lowering LDL-C. However, different types of statin 
show a different degree of LDL-C reduction at therapeutic doses 
[56]. Of the clinically approved statins, rosuvastatin is the most 
effective at lowering LDL-C, with reductions of up to 63% followed 
by atorvastatin, pitavastatin, and simvastatin with the LDL-C 
reduction of 50%, 48% and 41% respectively [57]. The ability of 
statins to increase HDL-C levels is also shown at varying degrees. 
Results by comparative trials confirmed that at 10-40 mg doses, 
rosuvastatin increased HDL-C level by 7.7–9.6% as compared to that 
of 2.1–5.7%, 5.2–6.8% and 3.2–5.6% as in the case of atorvastatin, 
simvastatin and pravastatin respectively [58]. 
In general, statins are well tolerated and their safety is well 
established. However, statin has been reported to effect liver and 
muscular tissue adversely. Although the incident of myotoxicity is 
low (approximately one in 1000 patients treated) it can lead to a 
fatal rhabdomyolysis [59]. The incident of fatal rhabdomyolysis in a 
number of patients treated with cerivastatin in 2001 has become an 
eye opener for the researchers to emphasize seriously the adverse 
reaction of other statin molecules. On the other hand, it must be 
stressed here that, high incidents of myopathy can be triggered if an 
inhibitor of cytochrome P450 or other inhibitors of statin 
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metabolism are administered together with a statin that increases 
their concentration in blood. Other risk factor includes hepatic 
dysfunction, hypothyroidism, renal insufficiency, advanced age and 
serious infections [53].  
Beneficial effects of statin 
Besides being used extensively for the treatment of 
hypercholesterolemia, comprehensive research on statin molecules 
has led to the discovery of its therapeutics pleiotropic effects. These 
include anti-inflammatory [60] and antioxidative properties [61] 
neuroprotective activities [62], improvement of endothelial function 
and increased nitric oxide bioavailability [63]. These discoveries 
have increased the beneficial effects of statin therapy in the 
treatment of Acute Coronary Syndromes (ACS), renal failure, 
neurologic disorder and infectious disease [64].  
Recent studies on statin revealed that statin might be the suitable 
candidate for new chemotherapy for cancer disease. Its selective 
inhibition of HMGA-CoA reductase activities which resulted in the 
reduction of mevalonate and inhibit malignant cell proliferation 
[64]. Additionally, the administration of statin will increase the 
mineral density of the bones and decrease of bone fracture risk of 
the 50 y old patient [65]. 
Though the statins are highly recognized universally for their 
beneficial effects in reducing serum cholesterol and thereby 
preventing the morbidity and mortality associated with coronary 
heart disease, a lot of interest is getting surfaced for their potential 
benefits in the area of neurodegeneration disease such as 
cerebrovascular disease [66], Parkinson’s disease [67], Alzheimer’s 
disease [68] and multiple sclerosis [69]. Statins unique 
characteristics such as high potential blood-brain barrier 
penetration and cholesterol lowering effects on neuron fully 
explained their role in neuroprotective activities. 
Solubility issue 
Solubility which can be determined by the thermodynamic and 
kinetic method can be defined as the amount of a solute that can be 
dissolved in a fixed volume of solvent at a given temperature. 
Solubility is affected by various factors such as time, saturation 
degree of the solution, particle size, temperature and pH of the 
medium [4]. Solubility issue is one of the major technical problems 
among the pharmaceutical researchers involved in the 
pharmaceutical formulation development. The issue becomes more 
prominent when 40% of new chemical entities are poorly soluble or 
insoluble in water. Around 50% of orally administrated drugs are 
reported to have formulation problems related to low 
bioavailability, hence, become a core issue, and need to be addressed 
by the researchers [70]. The level of drug concentration in the 
systemic circulation of poorly soluble drugs is being affected mainly 
by the time required for the dosage form to release its contents and 
for the drug to dissolve. Therefore, improving the saturation 
solubility and dissolution rate of the poorly soluble drug is very 
crucial in order to achieve complete absorption. As mentioned 
previously, statin molecules are classified under class II drug (low 
solubility, high permeability) in BCS. Hence, in order for the drugs of 
this class to achieve complete absorption in the systemic circulation, 
they must be dissolved in the gastrointestinal fluid and release its 
content [71]. Numerous techniques and methods have been 
presented by previous scientific articles on the enhancement of 
statin molecules solubility. In this review, all technique reported will 
be divided into 4 main categories ie solid dispersion technique, 
inclusion complex formation technique, solubilization of surfactant 
technique and particle size reduction technique. The detailed review 
of all techniques are illustrated in table 3-9.  
Solubility enhancement strategies 
Solid dispersion 
Solid dispersion can be defined as the dispersion of one or more 
active ingredients in an inert carrier matrix at solid state [72]. Since 
its introduction in 1960s by Sekiguchi and Obi, the system has been 
widely used to improve the solubility, the dissolution rate and 
bioavailability of poorly water soluble drugs [73]. In solid dispersion 
systems, the physicochemical interactions occur between 
hydrophobic drug and the carrier which involved the deposition of 
the drug on the surface of an inert carrier. This will lead into the 
alteration of the dissolution and solubility characteristics of the 
drug. Various explanation and theories have been proposed by the 
researchers on this phenomenon. These include the reduction of the 
particle size, the increased in the surface area, the increased in 
wettability due to the presence of hydrophilic carriers, the high 
porosity of the particles, the reduction of aggregation and the possible 
presence of the drug in its amorphous form [74]. Solid dispersion 
approach also offers numerous advantages such as simple and 
economical process, flexibility in formulation, provide great stability, 
allow dose combination and no use of toxic constituents [4]. Based on 
those advantages it is no doubt that this approach is preferred by most 
researchers in order to improve the solubility of poorly water soluble 
drugs. Basically, solid dispersion system can be prepared by 4 main 
methods ie melt/cool (fusion) method, solvent evaporation, co-
precipitation and dropping method. The list of technique categorized 
under those methods can be seen in table 2. 
 
Table 2: Solid dispersion techniques 
Melt/cool method Melting solvent method 
Hot stage extrusion 
Solvent evaporation Hot plate drying 
Vacuum drying 






Co-precipitation Addition of a anti-solvent 
Dropping method  
 
Based on our scientific articles compilation, solid dispersion became 
the main approach used by the researchers in their attempt to 
enhance the solubility of statin molecules. It has been used for four 
statin molecules namely simvastatin, lovastatin, atorvastatin and 
rosuvastatin. Simvastatin and atorvastatin are the most studied 
statin molecules for solubility enhancement (table 3a and 3b). This 
might be due to the fact that both molecules are the most commonly 
used lipid-lowering agents being prescribed by the medical 
practitioners [75]. Solvent evaporation method was the commonly 
method used to produce a solid dispersion. In solvent evaporation, 
both the drug and the carrier are dissolved in a common solvent 
followed by the evaporation of the solvent to form a solid solution. 
Major advantage of this method is the usage of low temperature 
during organic solvent evaporation which can prevent thermal 
degradation of drug or carrier. The used of HPMC K3LV as a polymer 
at a proposition of 1:1 to the amount of simvastatin followed by 
evaporation by spray dryer resulted 18.6 fold increase in 
simvastatin solubility [76]. Other studies derived the same trend of 
simvastatin solubility enhancement ie 2.6 and 4.46 fold [77], 8.5 fold 
[78] and 4.1 fold [79]. The same trend of solubility enhancement 
was reported for other statin molecules ie 1.5-2.9 fold for lovastatin 
[80, 81], 2-33 folds for atorvastatin [82-84, 134] and 4.7 fold for 
rosuvastatin [85]. The results of other solid dispersion approaches 
used are summarized in table 3a and b. In conclusion, solid 
dispersion becomes a key focus emphasized by the researchers due 
to the facts that the method can be easily scaled up, provide great 
stability, lower manufacturing cost and allow dose combination. 
Inclusion complex  
Inclusion complex formation is one of the most studied techniques 
used to enhance the solubility, dissolution rate and successively 
improved the bioavailability of poorly soluble drug [86]. It can be 
defined as the formation of a complex by addition of the non-polar 
molecules or guest substance, into other molecules or host. 
Cyclodextrins, (CD) which are cyclic oligosaccharides obtained by 
the enzymatic degradation of starch are the most widely used host. 
It can be divided into 3 main types namely α, β and γ base on the 
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number of monomers in the macrocycle (6, 7 and 8 glucopyranose 
units respectively) [87]. It god a unique molecular structure where 
its cylinder shape consists of a hydrophobic inner cavity and a large 
number of the hydroxyl group on the outer surface, that explain its 
water soluble characteristic [88]. Due to this distinctive feature, CD 
are capable of forming inclusion complexes with poorly water-
soluble compound by taking up a lipophilic part of the guest 
molecules into its cavity without forming any covalent bonds [89]. 
Numerous scientific research has been reported on the capability of 
CD inclusion to improve poorly water soluble molecules solubility 
and stability such as piroxicam [90], glipizide [91], ibuprofen [92], 
and itraconazole [93]. Basically, there are 5 techniques usually 
employed in producing CD inclusion complexes. These include 
kneading, co-evaporation, lyophilization, spray drying and 
extraction in the supercritical fluid. The details of each method 
employed are summarized in table 4a-b. 
Based on our compilation, kneading became the main approach used 
by the researchers in their attempt to enhance the solubility of statin 
molecules. In kneading statin molecules and CD are mixed with a 
small amount of water or hydroalcoholic mixture and the complex 
formed was dried in air or oven. This approach has been reported 
for three statin molecules namely simvastatin, lovastatin, and 
rosuvastatin. The ternary inclusion complexation of simvastatin 
with βCD and Soluplus ® (polymeric solubilizer with an amphiphilic 
chemical structure) resulted 55 fold increase in simvastatin 
solubility [94]. An increase of 3.4 fold on simvastatin solubility was 
also reported by Mandal et al. in 2010 [95]. The same trend of 
solubility enhancement was also reported for other statin molecules 
such as 3.4 and 1.54 fold for lovastatin [96] and rosuvastatin [97] 
respectively. Another inclusion complex formation involving other 
approaches has shown the same trend on statin molecules solubility. 
Jun et al., 2006 [98] reported 8 fold increase in simvastatin solubility 
from the βCD-Simvastatin complex prepared with the supercritical 
anti-solvent method. Palanisamy et al., 2016 [135] reported 35.8 
fold increase in atorvastatin solubility from the binary systems with 
HPβCD using freeze drying method at drug: carrier ratio of 1:5. An 
interesting attempt was performed on βCD inclusion complexes, 
where simvastatin and lovastatin were dissolved in a liposomal 
dispersion of L-α-dipalmitoyl phosphatidylcholine (DPPC). The 
solubility enhancement of both molecules was reported at 9 times as 
compared to the complexes which was derived from βCD alone [87]. 
The results of other inclusion complex studies are summarized in 
table 4. In conclusion, complex inclusion approach has also been 
employed for improving the solubility of statin molecules. However, 
low drug loading is one of the drawbacks this method suffers with. 
 
Table 3a: Solubility enhancement of statin molecules by solid dispersion approach (1) 
Statin 
molecules 






1:31:3 2.64.46 Rao et al., 
(2010) [77] 
Hydroxypropyl methyl 




12.718.6 Pandya et al., 
(2008) [76] 
Solvent evaporation  PEG 6000, sorbitol, 
Gelucire 44/14 
1:1:1 (Fusion) 8.5 Jatwani et al., 
(2011) [78] 
Fusion method PEO-PPO block 
copolymers 
1;4 4.7 times greater than pure 
drug (dissolution medium 
phosphate buffer 
Singh et al., 
(2012) [125] 
Physical mixture Oat powder 1:3 3.1 times greater than pure 
drug (dissolution medium–
phosphate buffer 





*Methocel E3 LV 
(HPMC)**Methocel E3 LV 
(HPMC) and propylene 
glycol 
1:41:8.3:0.7 4.1 3.6 Javeer et al., 
(2013) [79] 
 
Table 3b: Solubility enhancement of statin molecules by solid dispersion approach (2) 
Statin 
molecules 
Methods Excipient Drug-carrier 
ratio 
Increase in solubility (times) Reference 





1:2:2 2 (in SIF)1.5 (in SGF) Shaik et al., (2011) [80] 
Modified locust bean 
gum 
1:5 2.9 Patel et al., (2008) [81] 
Atorvastatin Solvent evaporation Skimmed milk 1:9 33 Choudharya et al., (2012) 
[84] 
HPMC 2:1 2 Uddin et al., (2010) [82] 
Nicotinamide 1:1 2 Shayanfar et al., (2013) 
[83] 
Hot melt extrusion  PEG 4000 1:5 2 Bobe et al., (2011)[127] 
Dropping method PEG 6000 1:3 2.2 Lakshmi et al., (2011)[128] 







5% (w/v) in 
methanol1(Dru
g):1(PVP VA64) 
1.4 in bioavailability than the 
amorphous atorvastatin 
nanoparticle 
Kim et al., (2008)[129] 
Rosuvastatin Spray drying  PVP K30 1:6 4.7 times greater than pure drug 
(dissolution medium–pH 6.8 of 
phosphate buffer) 
Swathi et al., (2013) [85] 
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Table 4a: Solubility enhancement of statin molecules by complex inclusion approach (1) 
Technique Methods Excipient Drug-
carrier 
ratio 
Increase in solubility (times) Reference 
Simvastatin Simple physical mixing, 





1:1:0.005 55 Taupitz et al., 
(2013) [94] 
Supercritical anti-
solvent (SAS) method 
Hydroxypropyl-β-
cyclodextrin 
1:1 12.2 Jun et al., 
(2006) [98] 
Cyclodextrin complex 
in liposomal dispersion 




Drug solubility was proportional to the 
quantity of methylated β cyclodextrin in 
liposomal dispersion around 9 times  




1:1 3.4 times greater than pure drug 
(dissolution medium–phosphate buffer 
Mandal et al., 
(2010) [107] 
Lovastatin Not mentioned 
specifically 




79 Csempesz et al., 
(2010) [87] 
Kneading β Cyclodextrin 1:1 3.4 times greater than pure powder of 
lovastatin (dissolution medium–
phosphate buffer pH 6.8) 
Patel and Patel 
(2007) [96] 
 
Table 4b: Solubility enhancement of statin molecules by complex inclusion approach (2) 
Technique Methods Excipient Drug-carrier ratio Increase in solubility (times) Reference 
Atorvastatin Freeze dry Substituted 
derivative (HP β-
Cd) 
1:5 35.8 Palanisamy et al., 
(2016) [135] 
Rosuvastatin Freeze dry randomly 
methylated- 
β-CD (RM-β-Cd) 




Sodium salicylate  Excess rosuvastatin in 
0.2N sodium salicylate 
55 Nainwal et al., 
(2011)[131] 
Kneading method Β-cyclodextrin 1:1 1.54 times greater than pure drug 
(dissolution medium–pH 6.8 of 
phosphate buffer) 
Akbari et al. 
(2011) [97] 
 
Surfactant based approach  
Surfactant are usually organic compounds that are amphiphilic. Most 
of the surfactant consist of a hydrocarbon part that is attached to a 
polar group. This polar group can be anionic, cationic, zwitterionic 
or non-ionic. When hydrophobic molecules are introduced, it can be 
attached to the hydrophobic core of the micelles [99] resulted in a 
decrease in surface tension. The decrease in the surface tension will 
increase the solubility of the drug in aqueous solution. An attempt to 
enhanced statin molecules solubility with this method was reported 
for simvastatin, lovastatin and rosuvastatin. Margulis and Magdassi 
successfully obtained simvastatin nanoparticles form by solvent 
evaporation from spontaneously formed oil-in-water 
microemulsions. The nanoparticles formed showed a tremendous 
enhancement in dissolution profile ie 50 times greater compared to 
the conventional tablet [100]. Another attempt by Mandal reported 
for an increased in in vitro micro-emulsion lovastatin (LVS) release 
as compared to conventional suspension and commercially available 
lovastatin. This study also revealed for an increase of 4.7 times in 
bioavailability after oral administration of LVS formulation as 
compared with the commercially available lovastatin [95]. 
Self micro emulsifying drug delivery system (SMEDDS) and self nano 
emulsifying drug delivery system (SNEDDS) is another approached 
that commonly used to enhance the solubility of poorly soluble 
drugs. In SMEDDS and SNEDDS, the isotropic mixture of oil, 
surfactant and co-surfactant will form oil-in-water micro or 
nanoemulsion upon mild agitation, followed by administration into 
aqueous media such as GI fluid [101]. Based on our literature search, 
both methods has been used to enhance the bioavailability of 
simvastatin, lovastatin, and rosuvastatin. An increased in 
bioavailability has been reported for simvastatin-SMEDDS, 
lovastatin-SMEDDS and rosuvastatin-SNEDDS for about 1.5 [102], 
2.27 [136] and 2.45 fold [103] respectively as compared to the 
commercially available drug. Lipid nanoparticle (LN) is another 
approach that has been reported to increase the bioavailability of 
statin molecules. Simvastatin-LN obtained from the emulsification 
solvent evaporation mixture of Solutol® HS-15 (surfactant), oil and 
lecithin reported for a bioavailability increased in about 3.37 fold as 
compared to simvastatin suspension. The details of all approaches 
are summarized in table 5a-b.  
Particle size reduction  
Particle size reduction technique involved physical modification of 
the particle with the aim to increase particle surface area, solubility 
and wettability with the decrease in particle size. This technique 
focused on the particle size reduction or generation of amorphous 
state [104]. In typical part of formulation preparation, size reduction 
involved well-established media milling procedure such as high-
pressure homogenizer. In media milling, the drug particles are 
subjected to milling in the high energy shear forces generated from 
the impaction between the drug and the milling media [105]. This 
action will provide energy to reduce the drug from micro to nano 
sized particle. The implementation of supercritical antisolvent (SAS) 
approach in particle size reduction currently gained significant 
attention among the researches. This technique offer process 
efficiency, selectivity and accommodating the principles of green 
chemistry [108]. Sometimes nanonization technique is also used for 
particle size reduction [109]. Based on our literature search, the size 
reduction technique has being used to enhance the solubility and 
bioavailability for 3 statin molecules namely simvastatin, 
atorvastatin and lovastatin. Two studies are reported for 
atorvastatin solubility enhancement by media milling. The first 
attempt involved the formation of the nanosize chitosan-
atorvastatin (CH-AT) conjugate by high-pressure homogenizer 
milling. Nanoconjugate CH-AT shows a tremendous enhancement in 
atorvastatin solubility. It was reported that nanoconjugate of CH-AT 
showed solubility enhancement of nearly 4 fold and 100 fold 
compared to CH-AT conjugate and pure atorvastatin respectively 
[110]. Similar media milling approach was reported by Arunkumar 
[111] In this study, atorvastatin nanosuspension was formed by high 
speed homogenizer followed by high pressure homogenizer. An 
average size of 200 nm particle size of suspension was formed. This 
suspension managed to increase atorvastatin solubility for up to 3.4 
fold as compared to pure atorvastatin [111]. 
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Table 5a: Solubility enhancement of statin molecules by surfactant based approach (1) 
Technique Methods Excipient Drug-carrier ratio Increase in solubility 
(times) 
Reference 









incorporated simvastatin and 
lyophilized (100 nm nanoparticles, 
10.8and Simvastatin). Tablets then 
made with 24% of freeze dried 
material 












Solutol ® HS-15, 
Miglyol 812, 
lecithin S-75 




Zhang et al., 
(2010) [106] 
Self micro emulsifying 





(7:37:28:28) for simvastatin: Capryol 
90,: Carbitol,: CremophorL 
1.5 increased in 
bioavailability compared 
to conventional tablet 
Kang et al., 
(2004) [102] 
 
Table 5b: Solubility enhancement of statin molecules by surfactant based approach (2) 
Technique Methods Excipient Drug-carrier ratio Increase in solubility (times) Reference 
Lovastatin Microemulsion Capmul® MCM 
Cremophor® EL 
Transcutol® P 
20 mg lovastatin with 7% 
Capmul® MCM 
24%Cremophor® EL 
8%Transcutol® P and 
water 
Approximately 1.3 times 




 Self micro emulsifying 
drug delivery system 
(SMEDDS) 
peanut oil, 
labrasol, span 80 
labrasol, span 80, peanut oil 
(40:20:40) 
2.27 times increased in 
bioavailability compared to raw 
lovastatin 
Yadava et al., 
(2015) [136] 
Rosuvastatin Self nanoemulsifying 





10 mg drug: 30% cinnamon 
oil: 60% labrasol: 10% 
capmul MCM C8 
1.72 times greater than 
marketed formulation 
(dissolution medium–pH 6.6 of 





Table 6: Solubility enhancement of statin molecules by size reduction 
Technique Methods Excipient Drug-carrier 
ratio 
Increase in solubility (times) Reference 
Simvastatin Nanonization Tween 80 0.5 (drug):1 
(tween) 
2.6 times increased in 
bioavailability compared to 
conventional drug 




Supercritical CO2,  
Methanol 
4% (w/v) in 
methanol 
1.8 times increased in 
bioavailability compared to 
conventional drug 
Chavhan et al., 
2013 [105] 
 Rapid expansion of 
supercritical solution  
NA NA 4 fold increased in dissolution rate  Fattahi et al., 
2016 [132] 
Lovastatin nanocrystal Acetone 3 mM Drug in 
organic solution  
18  Nanjwade et al., 
(2011) [109] 
 Coacervation phase 
separation 
Ethanol, 
Eudragit® L 100, 
SDS  
drug: polymer: 
SDS 1:2: 0.25% 
4 fold increased in dissolution rate Al-Nimry et al., 
2016 [133] 
Atorvastatin High pressure 
homogenization and spray 
drying 
Polaxomer 188 10 (Drug): 1 
(Surfactant)  
3.4 Arunkumar et 
al., (2009) [111] 
Supercritical anti-solvent 
(SAS) method  
Supercritical CO2, 
Acetone 
10 % (w/v) in 
acetone 




5 % (w/v) in 
methanol 








Approx 1.2 times greater than 
atorvastatin powder (dissolution 
medium–phosphate buffer 
Zhang et al., 
(2009) [114] 
Chitosan–atorvastatin 
conjugate and High Pressure 
Homogeniser 
Chitosan 10:1 100 fold than pure atorvastatin Anwar et al., 
(2011) [110] 
 
Table 7: Solubility enhancement of statin molecules by drug-dentrimer conjugates approach 
Technique Methods Excipient Drug-carrier ratio Increase in solubility (times) Reference 
Simvastatin  PEG-PAMAM dentrimer Not mentioned 33 Kulhari et al., (2011) [116] 
NH2–PAMAM dentrimer 23 
OH-PAMAM dentrimer 17.5 
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As been mentioned in the early part of this section, SAS approach is a 
promising technique that has been given significant attention among 
the researches recently. In SAS, the drug will be dissolved in the 
solvent and will be introduced into the temperature and pressure 
equilibrated particle precipitation vessel which has being filled with 
the constant rate of Supercritical CO2(Sc-Co2) [112]. In this vessel, 
precipitation will forms instantaneously by a rapid desolvation of 
the drug. At washing step, the SC-CO2 will wash out the residual 
content of solvent solubilized in the supercritical anti-solvent [112]. 
This technique has been successfully used for simvastatin and 
atorvastatin solubility and bioavailability enhancement. Simvastatin 
prepared with SAS technique showed bioavailability increment (1.8 
times) compared to the plain drug [105]. The same trend has been 
reported by another 3 scientific publications on atorvastatin. All 
researchers concluded that this process has increased either the 
solubility or dissolution of the pure drug [112-114]. Another 
approach that has been explored by the researcher is nanonization, 
This approach was not using any surfactant and claimed to produce 
more soluble, biologically available and safer dosage form of the 
poorly soluble drug. Researchers reported, a nanocrystal of 
lovastatin obtained through nanonization showed an increased 
solubility for up to 18 folds as compared to the pure lovastatin [109]. 
Rapid expansion of supercritical solution (RESS) and coacervation 
phase separation are another approaches that have been reported to 
increase the dissolution rate of simvastatin and lovastatin by 4 and 5 
fold respectively [132-133]. The details of all approaches mentioned 
are summarized in table 6. 
Novel formulation approaches 
In this section some novel approaches are discussed so to highlight 
some possible methods of solubility enhancement, which may 
further be explored for the statins. 
 
Table 8: Solubility enhancement of statin molecules by mesoporous carrier approaches 
Technique Methods Excipient Drug-carrier 
ratio 






1: 0.2 4.5 Zhang et al., 
(2013) [118] 









3.3 times greater than pure powder of 
lovastatin (dissolution medium–
enzyme-free buffer with 0.10% SDS 
(pH 6.8)  
Zhao et al., 
(2012) [119] 
Porous silica monolith 
(PSM) 
1:3 1.8 times greater than pure powder of 
lovastatin (dissolution medium–
phosphate buffer with 0.20% SDS 
(pH 7) 
Chao Wu et al., 
(2012) [117] 
 
Table 9: Solubility enhancement of statin molecules by liquid-solid system approach 






Avicel PH 102, Aerosil 200, 
Sodium starch glycolate  
10% w/w drug in PG, 20: 1 
ratio of Avicel, and Aerosil, 10% 
explotab 






Rosuvastatin Propylene glycol 
Microcrystalline cellulose, 
Aerosil 200, Sodium starch 
glycolate  
10% w/w drug in PG, 166.6 mg 
Avicel, 8.33 mg Aerosil, 5% 
Sodium starch glycolate 
Approx 2 times greater than 
marketed formulation 
(dissolution medium–300 ml 
distilled water) 
Kapure et al., 
(2013) [124] 
PEG200, Avicel PH,Aerosil 
200, Sodium starch 
glycolate 
15% w/w drug in PEG 200, 
305.77 mg Avicel, 10.19 mg 
Aerosil,17.46 Sodium starch 
glycolate 
Approx 2 times greater than 
marketed formulation 
(dissolution medium–phosphate 
buffer PH 6.8) 




Dendrimers are large and highly branched complex molecules with 
very well defined 3D chemical structure. It’s having a nanoscale 
structure with very low polydispersity and high functionality [115]. 
A dendrimer is inert and small enough to pass through the cell and 
can be used to deliver the drug to the targeted cell. There are three 
basic family of dendrimer namely poly (amidoamine) (PAMAM), 
diamino butane (DAB) and polypropylene imine (PPI). As the first 
synthesis dentrime, PAMAM has been extensively used as a drug 
carrier in drug delivery. PAMAM unique characteristics such as 
allowing the precise control of the size, shape and placement of the 
functional group, provide minimum toxicity and widely available 
make it the right candidate for an ideal drug carrier. PAMAM has 
been reported to form a conjugate with simvastatin in order to 
improve simvastatin aqueous solubility [116]. The effect of PAMAM 
concentration, pH and the type of functional group attached to the 
dendrimer was also assessed in this study. This study showed a 
significant enhancement on simvastatin solubility among 
Simvastatin-PAMAM conjugates. A 33 fold increment on simvastatin 
solubility is reported for PEGlated dendrimer simvastatin followed 
by amine (23 times) and hydroxyl (17.5 times) dendrimer [116]. The 
positive finding of this study can become the catalyst for more 
studies on other statin molecules-dendrimer conjugates. The details 
of the study reported by Kulhari are summarized in table 7. 
Mesopourous carrier 
The porous material can be defined as the material with an ordered 
or irregular arrangement of different pore size ranging from 
nanometer to millimeter. These highly pourous materials provide a 
large effective surface area and hydrophilic surface. Its unique 
characteristic such as biocompatible, not toxic, stronger 
adsorbability and structural versatility has attracted the attention of 
recent studies on their capability to enhance the solubility of poorly 
soluble drug [117]. Two studies are reported on the solubility 
enhancement of lovastatin by this approach. Wu, investigating the 
feasibility of 2 novel starch-derived porous material namely porous 
silica monolith (PSM) and Porous Starch Foam(PSF) in improving 
the dissolution of lovastatin. In this study lovastatin was loaded into 
PSM (LV-PSM) and PSF (LV-PSF) by solvent exchange method. This 
study showed a significant increase in dissolution rate of LV-PSM 
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and LV-PSF. Both complex exhibit more than 80% release of 
lovastatin at 45 min in comparison with 50% release for the pure 
lovastatin [117]. The same trend of results was reported by Zhao et 
al. lovastatin loaded in uniform mesopourous silica spheres (LV-
UMCS) showed an increased in lovastatin accumulated released. 
More than 90% of lovastatin in LV-UMCS was released at 45 min in 
comparison with 20% release for the pure lovastatin [119]. Another 
study on simvastatin loaded in highly ordered mesoporous carbon 
(SIM-HMC) also reported an increased 4.5 fold release as compared 
to the pure powder of simvastatin [118]. The details of the study 
reported regarding this approach are summarized in table 8.  
Liquid-solid system 
Liquid-solid system are acceptably flowing and compressible 
powder form of liquid medication [120]. In this system, poorly water 
soluble drug get dissolve in non-volatile solvent to form a liquid 
medication. Further, the system shall be blended with the carrier 
and coating material to form dry looking, non-adherent, free-flowing 
and readily compressible powder [121]. Basically various grades of 
lactose, starch and cellulose may be used as carrier and very fine 
particle size silica powders may be used as the coating material 
[122]. Liquid-solid compact normally form in a fine particle form. 
This characteristic will increase it molecules surface area that will 
enhanced dissolution characteristics and subsequently, oral 
bioavailability [123]. An attempt to improve statin molecules 
solubility with this approach reported by Gubbi and Jarag in 2010 
for atorvastatin. An increase in atorvastatin accumulated released of 
94.08 % is achieved at 60 min as compared to 46.61% release in 
case of the pure atorvastatin. The A-LS compact also showed an 
improvement in bioavailability compared to their directly 
compressed counterparts [120]. The same trend of enhancement of 
drug release rate and bioavailability has been reported for 
rosuvastatin. [124, 121]. The details of the study reported on this 
approach are summarized in table 9. 
CONCLUSION 
In this review, an attempt has been made to highlight systematically 
the emergence of statin-based molecules as the lipid-lowering 
medicament with due consideration to their therapeutics benefits, 
possible side effects and poor solubility characteristics. In this 
context, statin molecules which are categorized under class II BCS 
and play an important role in a lipid lowering activities demand 
better solution for its solubility and bioavailability problem. Various 
methods have been employed by the researchers to overcome this 
problem. Typical methods such as solid dispersion, inclusion 
complex, solubilization with surfactant and particle size reduction 
have been reported. Some innovative approaches such as drug-
dendrimer conjugate, mesopourous carrier and liquid-solid have 
also been discussed in this review articles. It is very difficult to 
conclude which approach is better than the others since there are 
several factors that can influence the success of the given method. 
The assumption cannot be made just on the solubility and 
dissolution studies alone that are mentioned in some of the articles 
since it is really necessary to relate it with in vivo experiment. Another 
aspect that need to be addressed by the researchers is on the stability of 
the product formed through the implementation of the approaches. This 
is due to the facts that statin molecules show very high stability in 
crystalline form. Any attempt to change its structure from crystalline to 
amorphous derivatives demand a thorough investigation on its stability. 
Lastly, the effects of physical and chemical changes of statin on its 
pharmacokinetics need to be addressed adequately, which the author 
notice are lacking in most of the articles collected in this review.  
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